-+ 0.00%
-+ 0.00%
-+ 0.00%

ZAI LAB ANNOUNCES DOSING OF FIRST PARTICIPANT IN GLOBAL PHASE 1/1B STUDY OF ZL-1503, AN IL-13/IL-31R BISPECIFIC ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS

路透·12/08/2025 12:00:02

登錄查看新聞詳情